Militello John 4

What Happened John Militello (reporting person) received equity awards from Rocket Pharmaceuticals (RCKT) on February 11, 2026. The filing shows 29,982 restricted stock units (RSUs) granted (acquired at $0) and a derivative award representing a right to purchase 45,018 shares (also reported as acquired at $0). No cash was paid for the awards in this filing.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (appears timely).
• Awards: 29,982 RSUs (convert 1-for-1 to common stock) and a derivative award for 45,018 shares (option-like right).
• Price: Reported acquisition price $0 for both items (award/grant).
• Vesting: One-third vests February 11, 2027; remaining shares vest in equal quarterly installments over the following two years (applies to both RSUs and the 45,018-share option), subject to continued employment.
• Holdings after transaction: Not specified in the provided excerpt; footnote confirms RSUs convert to common stock on a one-for-one basis.
• Filing timeliness: Report filed two days after the transaction date; no late filing flag in the provided data.

Context

• These transactions are awards/grants, not open-market purchases or sales — they do not represent immediate cash proceeds or a sale of shares.
• The 45,018-share entry is a derivative award (a right/option to acquire shares) with a multi-year vesting schedule rather than an exercised option.
• For retail investors, grants signal management/company compensation alignment but are routine and subject to vesting and employment conditions; they are not the same as an outright cash purchase of stock.